220 related articles for article (PubMed ID: 36403055)
21. Increased susceptibility to septic and endotoxic shock in monocyte chemoattractant protein 1/cc chemokine ligand 2-deficient mice correlates with reduced interleukin 10 and enhanced macrophage migration inhibitory factor production.
Gomes RN; Figueiredo RT; Bozza FA; Pacheco P; Amâncio RT; Laranjeira AP; Castro-Faria-Neto HC; Bozza PT; Bozza MT
Shock; 2006 Nov; 26(5):457-63. PubMed ID: 17047515
[TBL] [Abstract][Full Text] [Related]
22. SOX9: Advances in Gynecological Malignancies.
Chen H; He Y; Wen X; Shao S; Liu Y; Wang J
Front Oncol; 2021; 11():768264. PubMed ID: 34881182
[TBL] [Abstract][Full Text] [Related]
23. C-C motif chemokine ligand 2/C-C receptor 2 is associated with glioma recurrence and poor survival.
Yang Q; Zhang J; Zhang X; Miao L; Zhang W; Jiang Z; Zhou W
Exp Ther Med; 2021 Jun; 21(6):564. PubMed ID: 33850536
[TBL] [Abstract][Full Text] [Related]
24. A role for CCL2 in both tumor progression and immunosurveillance.
Li M; Knight DA; A Snyder L; Smyth MJ; Stewart TJ
Oncoimmunology; 2013 Jul; 2(7):e25474. PubMed ID: 24073384
[TBL] [Abstract][Full Text] [Related]
25. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis.
Sanford DE; Belt BA; Panni RZ; Mayer A; Deshpande AD; Carpenter D; Mitchem JB; Plambeck-Suess SM; Worley LA; Goetz BD; Wang-Gillam A; Eberlein TJ; Denardo DG; Goedegebuure SP; Linehan DC
Clin Cancer Res; 2013 Jul; 19(13):3404-15. PubMed ID: 23653148
[TBL] [Abstract][Full Text] [Related]
26. CCL2 increases αvβ3 integrin expression and subsequently promotes prostate cancer migration.
Lin TH; Liu HH; Tsai TH; Chen CC; Hsieh TF; Lee SS; Lee YJ; Chen WC; Tang CH
Biochim Biophys Acta; 2013 Oct; 1830(10):4917-27. PubMed ID: 23845726
[TBL] [Abstract][Full Text] [Related]
27. Roles of CCL2-CCR2 Axis in the Tumor Microenvironment.
Kadomoto S; Izumi K; Mizokami A
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445235
[TBL] [Abstract][Full Text] [Related]
28. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds.
Lança T; Costa MF; Gonçalves-Sousa N; Rei M; Grosso AR; Penido C; Silva-Santos B
J Immunol; 2013 Jun; 190(12):6673-80. PubMed ID: 23686489
[TBL] [Abstract][Full Text] [Related]
29. IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction.
Shahrara S; Pickens SR; Mandelin AM; Karpus WJ; Huang Q; Kolls JK; Pope RM
J Immunol; 2010 Apr; 184(8):4479-87. PubMed ID: 20228199
[TBL] [Abstract][Full Text] [Related]
30. Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma.
Sica A; Saccani A; Bottazzi B; Bernasconi S; Allavena P; Gaetano B; Fei F; LaRosa G; Scotton C; Balkwill F; Mantovani A
J Immunol; 2000 Jan; 164(2):733-8. PubMed ID: 10623817
[TBL] [Abstract][Full Text] [Related]
31. CCL3/CCR1 mediates CD14
Zhao X; Gu M; Xu X; Wen X; Yang G; Li L; Sheng P; Meng F
Osteoarthritis Cartilage; 2020 May; 28(5):613-625. PubMed ID: 32006659
[TBL] [Abstract][Full Text] [Related]
32. [Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].
He Y; Wang Y; Ji C; Liu Y; Wu YM
Zhonghua Fu Chan Ke Za Zhi; 2022 May; 57(5):352-360. PubMed ID: 35658326
[No Abstract] [Full Text] [Related]
33. Estrogen promotes progression of hormone-dependent breast cancer through CCL2-CCR2 axis by upregulation of Twist via PI3K/AKT/NF-κB signaling.
Han R; Gu S; Zhang Y; Luo A; Jing X; Zhao L; Zhao X; Zhang L
Sci Rep; 2018 Jun; 8(1):9575. PubMed ID: 29934505
[TBL] [Abstract][Full Text] [Related]
34. Application of natural polysaccharides and their novel dosage forms in gynecological cancers: therapeutic implications from the diversity potential of natural compounds.
Li Y; Zhang C; Feng L; Shen Q; Liu F; Jiang X; Pang B
Front Pharmacol; 2023; 14():1195104. PubMed ID: 37383719
[TBL] [Abstract][Full Text] [Related]
35. CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4.
Korbecki J; Kojder K; Simińska D; Bohatyrewicz R; Gutowska I; Chlubek D; Baranowska-Bosiacka I
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33182504
[TBL] [Abstract][Full Text] [Related]
36. Constitutive expression of CCR2 chemokine receptor and inhibition by MCP-1/CCL2 of GABA-induced currents in spinal cord neurones.
Gosselin RD; Varela C; Banisadr G; Mechighel P; Rostene W; Kitabgi P; Melik-Parsadaniantz S
J Neurochem; 2005 Nov; 95(4):1023-34. PubMed ID: 16150057
[TBL] [Abstract][Full Text] [Related]
37. Heterodimerization of CCR2 chemokines and regulation by glycosaminoglycan binding.
Crown SE; Yu Y; Sweeney MD; Leary JA; Handel TM
J Biol Chem; 2006 Sep; 281(35):25438-46. PubMed ID: 16803905
[TBL] [Abstract][Full Text] [Related]
38. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
[TBL] [Abstract][Full Text] [Related]
39. The regulation and importance of monocyte chemoattractant protein-1.
Bianconi V; Sahebkar A; Atkin SL; Pirro M
Curr Opin Hematol; 2018 Jan; 25(1):44-51. PubMed ID: 28914666
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological Targeting of the CCL2/CCR2 Axis for Atheroprotection: A Meta-Analysis of Preclinical Studies.
Živković L; Asare Y; Bernhagen J; Dichgans M; Georgakis MK
Arterioscler Thromb Vasc Biol; 2022 May; 42(5):e131-e144. PubMed ID: 35387476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
